MindWalk Unveils B Cell Llama Nanobody Platform Backed by Peer-Reviewed Study

MindWalk Holdings ( (HYFT) ) has shared an update.

On March 6, 2026, MindWalk Holdings announced B Cell Llama, a new nanobody discovery platform built to generate llama-derived VHH single-domain antibodies for bispecifics, multispecific therapeutics and CAR-T cell therapies. The system extends its B Cell Select technology by directly harvesting VHH nanobodies from immunized llamas and layering LensAI across target selection, candidate triage and multispecific construct modeling.

The launch is backed by a peer‑reviewed Biomacromolecules study showing that modular VHH formats can boost potency 10–25 times, overcome variant resistance where approved antibodies fail and potentially prime long‑term immune memory. MindWalk, which holds first rights to commercialize joint IP from the work, positions B Cell Llama as a key pillar of its bio-native AI strategy and pipeline in areas such as dengue, universal influenza, GLP‑1 and longevity therapeutics, and ALK‑1 oncology, aiming to capture a share of the fast‑growing bispecific and cell therapy markets.

The most recent analyst rating on (HYFT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

Spark’s Take on HYFT Stock

According to Spark, TipRanks’ AI Analyst, HYFT is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses and negative cash flow) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improved gross margin, and a stronger cash position, but valuation remains constrained by negative earnings.

To see Spark’s full report on HYFT stock, click here.

More about MindWalk Holdings

MindWalk Holdings Corp. (NASDAQ: HYFT) is a bio-native AI company focused on transforming the discovery and development of therapeutics, vaccines and diagnostics. Its HYFT and LensAI platforms turn biological sequence, structure, function and literature data into a unified computational language, supporting more than 15 molecules that have advanced to clinical stage across infectious disease, metabolic, oncology and nanobody-based programs.

Average Trading Volume: 468,000

Technical Sentiment Signal: Sell

Current Market Cap: $54.63M

Find detailed analytics on HYFT stock on TipRanks’ Stock Analysis page.